Thursday, April, 18, 2019 09:12:40

Contribution By Shikha Sinha


Dr. Reddy’s Laboratories acquires 42 ANDAs portfolio in the U.S.

The portfolio in question includes over 30 generic injectable products.  The latest acquisition expands Dr. Reddy’s current portfolio by a considerable margin. Dr. Reddy’s Laboratories Ltd., (Dr. Reddy’s), a renowned Indian multinational pharmaceutical firm based out of Hyderabad, has reportedly entered into a definitive agreement …

Catalent Inc to acquire Paragon Bioservices in a $1.2 billion deal

The acquisition would be helping Catalent in expanding its capabilities of developing costly & specialized gene therapy treatments. The company would be carrying out the acquisition through an all-cash deal, scheduled to be announced soon. Catalent, Inc., (Catalent), a New Jersey-based technology & pharmaceutical firm, …

Cerner and naviHealth to add a new offering to BPCI Advanced program

Cerner and naviHealth have reportedly expanded their relationship in a bid to introduce new offerings for bundled payments for care improvement advanced (BPCI Advanced) program, projected to support inexpensive and accessible healthcare centered on the patient. As per BPCI Advanced, benefactors prospectively approve a pre-defined …

GlaxoSmithKline Plc receives U.S FDA approval for HIV drug Dovato

One of the world’s leading pharma company GlaxoSmithKline Plc has reportedly attained the approval of the U.S. FDA for marketing its two-drug treatment for HIV infections, thereby boosting its growth prospects against rival Gilead Sciences Inc. As per trusted sources, the U.S. FDA cleared Dovato, …

Novacyt, Immunexpress expand contract for developing diagnostic assays

The partnership expansion would further support the development of rapid diagnostic assays needed for detecting sepsis Novacyt, a global clinical diagnostics specialist, has recently announced that Primerdesign Ltd, its molecular testing division, has expanded its assay development contract with Immunexpress, Inc., a molecular diagnostic company …

Aeglea presents positive data for Pegzilarginase to treat ARG1-D

The clinical-stage biotechnology company, Aeglea BioTherapeutics Inc., has reportedly announced positive Phase 1/2 data for Pegzilarginase to be used in the treatment of patients with ARG1-D (Arginase 1 Deficiency). Dr. George Diaz, Ph.D., M.D., Division Chief of Medical Genetics, Icahn School of Medicine, New York, …